Home » Saladax Approved to Sell New Antipsychotic Blood Tests in Europe
Saladax Approved to Sell New Antipsychotic Blood Tests in Europe
Devices Submissions and Approvals
Saladax Biomedical is clear to sell two new tests for antipsychotics on the European market after receiving a CE Mark.
The new products in the company’s MyCare Psychiatry line of antipsychotic tests measure total risperidone or paliperidone in the patients’ blood. The tests could help physicians by providing objective evidence of medication levels in clinically-relevant time.
The tests for antipsychotic blood levels could be used to evaluate adherence or to find reasons for lack of response or toxicity. Blood testing could also help determine the chance of clinical effect in patients treated with antipsychotics.